In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...
VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug ...
SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Neurelis, Inc., today announced a presentation on insights into study design from the enrollment process for the new Stellina study investigating VALTOCO® ...
One of the largest gatherings of people with epilepsy, care partners, and healthcare practitioners to address unmet needs for increased education SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Neurelis, Inc ...
Findings include analysis of seizure cluster treatment patterns with use of VALTOCO® (diazepam nasal spray) CIV and characterization of a diazepam dosing regimen in an animal model SAN DIEGO, April 11 ...
VALTOCO ® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results